PROTEOMICS - Clinical Applications
© WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Editor-in-Chief: Andrew Moore, Deputy Editor: Lucie Kalvodova
Impact Factor: 2.956
ISI Journal Citation Reports © Ranking: 2014: 26/79 (BIOCHEMICAL RESEARCH METHODS)
Online ISSN: 1862-8354
Associated Title(s): PROTEOMICS
Cover Picture: Proteomics – Clinical Applications 1/2008
In this issue of Proteomics you will find the following highlighted articles:
“When you have a good thing going, run with it” – Quote from paleolithic philosopher and hunting consultant. In this case, Thierolf et al. took a colon cancer sample set well-characterized by 2-DE-MALDI PMF and ran it through a 2-D-LC-ESI-MS protocol. The samples of malignant and normal tissues from the same patient, analyzed by 2-DE-MALDI and mass fingerprinting (reported elsewhere) yielded 734 unique proteins. When the same tissue specimens were analyzed by 2-D-LC-ESI-MS, 484 proteins were identified, 232 of them new and 252 that had been ID’d in the earlier work. The two unique sets exhibited similar functional and ontological profiles, confirming the complementarity of the two methods. Using the data to select up-regulated proteins for evaluation of potential for serving as biomarkers, they chose S100A12 as particularly interesting. An ELISA found that it was more sensitive but less discriminating than carcinoembryonic antigen. S100A12 is also an inflammation marker.
Thierolf, M. et al., Proteomics Clin. Appl. 2008, 2, 11–22
Standing at number five on the US cancer frequency list, urinary bladder cancer costs almost $3 billion a year. No acceptable early detection tests have been developed – it seems no one will volunteer for a “routine” annual cystoscopy, so the 5-year survival rate has stayed below 50% for many years. Several urinary biomarkers have been developed but fall short in their frequency of false positives or false negatives. Using 2-DE/MALDI-TOF MS and Ingenuity Systems’ Pathway Analysis software, Li et al. surveyed invasive urothelial carcinomas for up-regulated proteins and settled on Choroideremia-like protein (CHML) out of 21 candidates. Immunohistochemistry and Western blotting verified the specificity. The functional pathways found are part of the lipid metabolism, inflammation and molecular transport machinery and CHML is part of the Rab geranylgeranylation pathway. More work is needed to understand the diagnostic potential of CHML.
Li, J. et al., Proteomics Clin. Appl. 2008, 2, 78–89.
Angina, the chest pain associated with heart attacks, has two forms: stable (SAP) and unstable (UAP). SAP is relieved by rest. UAP pain persists at rest and is often due to formation of a clot which can lead to major or fatal damage (ischemia, myocardial infarct). The ability to distinguish the two would be a boon to hospital emergency care facilities because admission and intensive care are not required for SAP. Brown et al. report here the use of anti-leukocyte antibody arrays to analyze circulating cells by surface CD antigen type. Starting with 82 antibodies, they could readily distinguish healthy from SAP and UAP cases from 8 and 19 spot intensity differences, respectively. SAP and UAP could be separated with seven markers using spot intensity and cluster analysis, but not as cleanly, possibly because SAP has a tendency to convert to UAP.
Brown, A. et al., Proteomics Clin. Appl. 2008, 2, 90–98.